{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:10:18Z","timestamp":1789729818380,"version":"4.0.1"},"reference-count":34,"publisher":"Wiley","issue":"s5","license":[{"start":{"date-parts":[[2007,12,7]],"date-time":"2007-12-07T00:00:00Z","timestamp":1196985600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:p><jats:bold>Abstract\u2002<\/jats:bold> Two main types of safety procedures must be applied to biological products, including plasma derivatives: (i) preventive procedures and (ii) elimination procedures.Prevention includes epidemiological control of donor populations; checks on each donor\u2019s health condition; analysis of each donation for the main pathogens using serological methods; additional analysis of all plasma for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis A virus (HAV) and the B19 virus, using nucleic acid amplification techniques (NAT). A 60\u2003days or longer inventory hold of all plasma donations is applied, to allow additional time to discard previous donations from potential seroconverting or otherwise rejectable donors.Elimination procedures minimize the low residual risk of transmitting pathogens, including unknown or previously undetected ones. Since the introduction 20\u2003years ago of solvent\u2010detergent treatment, very effective against enveloped viruses (HIV, HBV, HCV, West Nile virus, SARS, avian influenza virus etc), there have been no known cases of transmission of this type of pathogens by products manufactured according to this procedure. Other inactivation procedures such as pasteurization, dry\u2010heat or nanofiltration may prove equally effective. In addition, dry\u2010heat treatment and nanofiltration are capable of effectively eliminating non\u2010enveloped viruses (HAV, B19 virus). Recent studies show that the B19 virus is much more sensitive to heat (in lyophilized state or by pasteurization) and acid pH than previously thought.Although there is no evidence for the transmission of classic transmissible spongiform encephalopathies (TSEs) through blood or blood\u2010products transfusion, four possible cases have been reported in the United Kingdom involving transmission by non\u2010leukoreduced blood components of the agent that causes variant Creutzfeldt\u2010Jakob Disease (vCJD), a disease linked to the outbreak of bovine spongiform encephalopathy (BSE) which took place in that country. However, there are no cases of human TSE (classic or variant) transmission by plasma\u2010derived products. Analytical methods capable of detecting the vCJD agent in patients\u2019 brains (where high titres are found) and other tissues (such as the spleen, appendix and lymph nodes, where much lower concentrations are found) are unable to detect the agent in blood or plasma from patients with vCJD, even in the clinical phase of the disease. Experiments by Grifols and other groups show that the capacity of the production processes to eliminate vCJD agent models is many orders of magnitude greater than the maximum expected load of the agent. In this regard, the efficacy of precipitation, affinity chromatography, depth filtration and nanofiltration are particularly notable.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2007.01578.x","type":"journal-article","created":{"date-parts":[[2010,9,15]],"date-time":"2010-09-15T13:46:44Z","timestamp":1284558404000},"page":"41-46","source":"Crossref","is-referenced-by-count":15,"title":["Safety procedures of coagulation factors"],"prefix":"10.1111","volume":"13","author":[{"given":"J. I.","family":"JORQUERA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,12,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1985.25686071422.x"},{"key":"e_1_2_6_3_2","first-page":"101","article-title":"West Nile virus: recent experience with the model virus approach","volume":"118","author":"Kreil TR","year":"2004","journal-title":"Dev Biol (Basel)"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01135.x"},{"key":"e_1_2_6_5_2","article-title":"Robustness study of specific virus inactivation steps in the manufacturing process of a high purity factor VIII concentrate, FANHDI","volume":"84","author":"Biescas H","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00158.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2003.00280.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05309.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00589.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00701.x"},{"key":"e_1_2_6_11_2","first-page":"93","article-title":"Variant CJD (vCJD) and bovine spongiform encephalopathy (BSE): 10 and 20\u2003years on: part 1","volume":"44","author":"Bradley R","year":"2006","journal-title":"Folia Neuropathol"},{"key":"e_1_2_6_12_2","volume-title":"Number of Cases of Bovine Spongiform Encephalopathy (BSE) Reported in the United Kingdom","author":"Office International Des Epizooties \u2013 OIE"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/66.1.185"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0701.010102"},{"key":"e_1_2_6_15_2","volume-title":"Number of Reported Cases of Bovine Spongiform Encephalopathy (BSE) in Farmed Cattle Worldwide (Excluding the United Kingdom)","author":"Office International Des Epizooties \u2013 OIE"},{"key":"e_1_2_6_16_2","volume-title":"Variant Creutzfeldt\u2010Jakob Disease \u2013 Current data","author":"The National Creutzfeldt\u2010Jakob Diesease Surveillance Unit"},{"key":"e_1_2_6_17_2","volume-title":"Analysis of the Risk of Transmission of the Variant Creutzfeldt\u2010Jakob disease by Medicinal Products of Human Origin and Labile Blood Products","author":"Agence Fran\u00e7aise de S\u00e9curit\u00e9 Sanitaire des Produits de Sant\u00e9","year":"2004"},{"key":"e_1_2_6_18_2","first-page":"32A","article-title":"An update on the Creutzfeldt\u2010Jakob disease look\u2010back study","volume":"45","author":"Zou S","year":"2005","journal-title":"Transfusion"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15486-X"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16811-6"},{"key":"e_1_2_6_21_2","volume-title":"4th Case of Variant CJD Infection Associated with Blood Transfusion","author":"Health Protection Agency"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00833.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38998409000.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3201\/eid0707.017731","article-title":"Emerging infectious disease issues in blood safety","volume":"7","author":"Chamberland ME","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615387"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1741-6892.2004.00444.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2006.11.001"},{"key":"e_1_2_6_28_2","first-page":"187","volume-title":"Biological Safety \u2013 Principles and Practices","author":"Baron H","year":"2000"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38998408999.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(99)00135-4"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41040449.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00216.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2005.00683.x"},{"key":"e_1_2_6_34_2","volume-title":"FDA\u2019s Transmissible Spongiform Encephalopathies Advisory Committee","author":"Food and Drug Administration"},{"issue":"2","key":"e_1_2_6_35_2","first-page":"5","article-title":"Efficacy of plasma derivatives purification processes to eliminate an experimental TSE\u2010model agent","volume":"12","author":"Biescas H","year":"2006","journal-title":"Haemophilia"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2007.01578.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2007.01578.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T07:19:37Z","timestamp":1695712777000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2007.01578.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":34,"journal-issue":{"issue":"s5","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1111\/j.1365-2516.2007.01578.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2007.01578.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}